Elekta is a Swedish medical-device company that makes cancer radiotherapy machines (linear accelerators, etc.) and, under its 'ACCESS 2025' strategy, brings radiotherapy to under-served regions. Low- and middle-income countries carry 80% of the global cancer burden but have only 32% of radiotherapy resources, and in low-income countries just one in ten can get life-saving treatment. Elekta has so far given 123 million cancer patients in such regions access to advanced radiotherapy. Partnering with the IAEA, it spreads care through training, digital tools and equipment, prioritizing BRICS+ and Southeast Asia.
B
NARRATIVE VALUE
Certainty
●●● high
●●● high
ABCDEFG
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3BHistory grows each quarter
Elekta: Bringing radiotherapy to regions short of cancer care. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
Cancer patients in regions with no radiotherapy machine nearby—in low-income countries, just one in ten can get life-saving radiotherapy. Through Elekta's machines and its IAEA partnership, advanced radiotherapy reaches such regions. The benefit appears as a collective: it has given 123 million cancer patients access to radiotherapy.
Source nature: Elekta / IAEA / P1 First-party / independent (IAEA). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- LMICs carry 80% of the global cancer burden but only 32% of radiotherapy resources—ACCESS 2025 prioritizes BRICS+ and Southeast Asia.P1 First-party / independent / Elekta
− effects (confirmed)
- No confirmed −.
Watching (unconfirmed; not counted in the assessment)
- A listed, for-profit device maker
- the device plus depends on hospitals'/clinicians' adoption and operation (indirect)
- reach figures are partly self-reported.
Looking ahead (not included in the assessment)
- Spreading radiotherapy further to low-income countries; assuring training and operational quality; verifying real outcomes of access; low-cost, labor-saving technology.
A second look
The plus is access to life-saving radiotherapy for cancer patients in under-served regions (People), backed by 123 million reached, the IAEA partnership, and redress of the '80% of burden, 32% of resources' gap. But it is a listed, for-profit device maker, and the device plus depends on hospitals' and clinicians' adoption and operation (indirect). Weighing the plus that answers cancer inequity, B/high.
Sources
+N1Elekta / IAEA｜Elekta-IAEA partnership; 123 million reached｜2025｜🔗
+ effectElekta｜New impact report on radiotherapy's role｜2025｜🔗
How to read this assessment
A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top